Angiofollicular Ganglionic Hyperplasia

Angiofollicular ganglionic hyperplasia (Castleman disease) is a rare disorder of the lymph nodes, which are small glands that help your immune system fight infection. In this disease, some lymph nodes grow too much and show special changes when doctors look at them under a microscope. The growth is non-cancerous (benign) in most cases, but it can still cause serious illness because the lymph nodes become large and the immune system releases many inflammatory chemicals (cytokines), especially interleukin-6 (IL-6).Wikipedia+3Cancer.gov+3NCBI+3

Angiofollicular ganglionic hyperplasia is another name for Castleman disease or angiofollicular lymph node hyperplasia. It is a rare disorder where lymph nodes grow too much and become enlarged, often because of over-active immune and inflammatory signals such as interleukin-6 (IL-6). This over-growth can be limited to one area (unicentric Castleman disease) or can affect many lymph node areas and organs (multicentric Castleman disease). Multicentric disease can cause fever, weight loss, night sweats, anemia, nerve damage, and a higher risk of lymphoma.

The disease can affect only one lymph node or one group of nodes (this is called unicentric disease) or many lymph nodes all over the body (this is called multicentric disease). When only one node is affected, many people have no symptoms, and the disease is often found by accident on a scan done for another reason. When many nodes are affected, the body can react with fever, weight loss, night sweats, severe tiredness, swelling of the liver and spleen, fluid build-up, and sometimes life-threatening organ failure.UAMS Health+3Cleveland Clinic+3Mayo Clinic+3

Under the microscope, the lymph node shows overgrowth of follicles (the “follicular” part) and many small blood vessels (“angio” means related to blood vessels). This is why the name “angiofollicular hyperplasia” was used. The disease is not a classic cancer, not a simple infection, and not a typical autoimmune disease; instead, it is a lymphoproliferative disorder with immune system over-activation and abnormal signaling.jpatholtm.org+3PubMed+3Orpha+3

---

Other names

Doctors and researchers have used several names for this condition over the years. They all refer to the same basic disease group:

• Castleman disease (CD) – the most common modern name, after the doctor who first described it.PubMed+2ScienceDirect+2

• Angiofollicular lymph node hyperplasia – very close to “angiofollicular ganglionic hyperplasia,” describing extra blood vessels (angio-) and overgrown follicles in the lymph node.Cancer.gov+1

• Giant lymph node hyperplasia – points to the very large size of affected lymph nodes.Wikipedia+1

• Lymphoid (or lymph nodal) hamartoma – a term meaning abnormal overgrowth of normal tissue elements in the lymph node.UPMC Path+1

These names may appear in older textbooks or pathology reports, but they are now usually grouped under Castleman disease.

---

Types of angiofollicular ganglionic hyperplasia

Doctors classify Castleman disease in several ways. Understanding these types helps to explain symptoms, tests, and treatment.

By number of lymph nodes involved (clinical types)

1. Unicentric Castleman disease (UCD)
   In unicentric disease, only one lymph node or one group of nearby nodes is affected. This is the most common form. It often occurs in the chest, neck, or abdomen. Many people with UCD have no symptoms, and the enlarged node is found by chance on imaging. When symptoms occur, they are usually due to the mass pressing on nearby structures (for example, chest pain or cough if the node presses on the lungs). Surgical removal often cures this form.SpringerLink+4Cleveland Clinic+4Mayo Clinic+4

2. Multicentric Castleman disease (MCD)
   In multicentric disease, many lymph nodes in different parts of the body are enlarged. It is often linked with strong immune activation and high levels of IL-6. People with MCD usually have systemic (whole-body) symptoms: fever, weight loss, night sweats, anemia, and enlarged liver and spleen. This form can be serious and sometimes life-threatening and often needs long-term medical treatment rather than just surgery.UAMS Health+4NCBI+4Mayo Clinic+4

By cause and virus status (etiologic types)

3. HHV-8–associated multicentric Castleman disease
   Some patients with multicentric disease are infected with human herpesvirus-8 (HHV-8), the same virus linked to Kaposi sarcoma. The virus can produce a form of IL-6 (viral IL-6) that drives inflammation and lymph node overgrowth. This type is often seen in people living with HIV or with other forms of immune suppression.eurobloodnet.eu+3PMC+3ASH Publications+3

4. Idiopathic multicentric Castleman disease (iMCD)
   In many other multicentric cases, no virus or clear trigger is found. These are called idiopathic MCD. Even without HHV-8, IL-6 and other cytokines still play a key role. Researchers think there may be autoimmune, genetic, or other unknown triggers.ResearchGate+3CDCN+3ASH Publications+3

By microscopic (pathologic) appearance

5. Hyaline-vascular variant
   This is the most common microscopic pattern, especially in unicentric disease. The lymph node follicles become small and atrophic in the center, with “onion-skin” rings around them and many small blood vessels with thickened (hyaline) walls. Pathologists sometimes describe a “lollipop” pattern where a blood vessel enters the center of a follicle. This variant often has few or no systemic symptoms.jpatholtm.org+3Blood Research+3CDCN+3

6. Plasma-cell variant
   In this variant, the lymph node contains many plasma cells (antibody-producing cells). People with this variant, especially when multicentric, often have more systemic symptoms such as fever, anemia, and high inflammatory markers, reflecting heavy cytokine production.Blood Research+2jpatholtm.org+2

7. Mixed or transitional variants
   Some lymph nodes show features of both hyaline-vascular and plasma-cell types. These mixed forms remind us that Castleman disease is a spectrum, not a single rigid pattern.Blood Research+1

---

Possible causes and risk factors

The exact root cause of angiofollicular ganglionic hyperplasia is still not fully known. Most of what we know is about risk factors and mechanisms that seem to trigger or maintain the disease. Many of the items below overlap and may act together.

1. Over-production of interleukin-6 (IL-6)
   IL-6 is a powerful immune messenger. In Castleman disease, IL-6 is often very high. It makes lymph nodes grow, increases antibody-producing cells, causes fever, raises C-reactive protein, and leads to anemia. Blocking IL-6 can improve symptoms, which shows how central it is to the disease.ResearchGate+3PMC+3ScienceDirect+3

2. HHV-8 (Kaposi sarcoma–associated herpesvirus) infection
   In HHV-8–associated multicentric disease, virus-infected cells in the lymph nodes produce viral IL-6, which acts like human IL-6 to drive inflammation and cell growth. This viral trigger is a key cause in that subgroup.Nature+3ASH Publications+3Johns Hopkins University Pure+3

3. HIV infection and immune suppression
   People with HIV have weakened and dysregulated immune systems. HIV infection is strongly linked with HHV-8 infection and with HHV-8-associated multicentric Castleman disease, making HIV an important risk factor.Nature+3ASH Publications+3EJCRIM+3

4. Chronic immune activation
   Long-lasting immune stimulation—from chronic infections or inflammatory states—may push lymphoid tissue to overgrow. Constant “alarm signals” can cause lymph nodes to enlarge and become hyperplastic.

5. Autoimmune tendencies
   Some patients with iMCD show features that overlap with autoimmune diseases, such as positive autoantibodies or connective tissue disease. This suggests that self-reactive immune responses may act as a trigger in some cases.Wikipedia+1

6. Genetic susceptibility
   Castleman disease is usually not inherited, but small studies suggest certain genetic or immune pathway differences may make some people more likely to develop it when exposed to triggers. Research is still ongoing.NCBI+2Rare Awareness Rare Education Portal+2

7. Other chronic viral infections (for example, EBV, hepatitis viruses)
   Chronic viral infections can keep the immune system activated. Epstein–Barr virus (EBV) and other viruses are sometimes found in lymphoid disorders, though their exact role in Castleman disease is less clear than HHV-8.

8. Association with POEMS syndrome
   Some patients with multicentric Castleman disease also have POEMS syndrome (a rare condition with neuropathy, organs enlarged, hormone problems, M-protein, and skin changes). In these patients, Castleman-type lymph node changes appear to be part of a broader plasma-cell disorder.NCBI+2Blood Research+2

9. Association with other lymphoid or plasma-cell disorders
   Castleman disease may coexist with lymphoma, multiple myeloma, or other lymphoid cancers. In those cases, abnormal immune cells and cytokines may contribute to Castleman-type lymph node changes.NCBI+2Blood Research+2

10. Chronic inflammation in the body (for example, autoimmune diseases)
    Conditions such as rheumatoid arthritis or other connective tissue diseases cause long-term inflammation. In some patients, this may provide a background for Castleman-like lymph node changes to develop.

11. Exposure to immunosuppressive drugs
    Strong immunosuppressive medicines (for example, after organ transplantation) can alter the balance of the immune system, increase risk of viral infections like HHV-8, and may indirectly lead to Castleman disease–like lymphoproliferation.

12. Organ transplantation and chronic immune modulation
    Transplant recipients often have chronic immune suppression and viral reactivation. Rarely, they can develop Castleman disease, likely due to the mix of viral triggers and altered immunity.

13. Dysregulated B-cell and plasma-cell responses
    In Castleman disease, B-cells and plasma cells can grow and divide more than normal in lymph nodes. This abnormal but usually non-cancerous proliferation is a core part of the disease process.PubMed+2Blood Research+2

14. Abnormal angiogenesis (too many blood vessels)
    The “angio” part of the name points to blood vessel overgrowth. Cytokines including IL-6 and VEGF (vascular endothelial growth factor) can stimulate new blood vessels, contributing to the characteristic microscopic appearance and sometimes to fluid retention and edema.CDCN+2jpatholtm.org+2

15. Bone marrow microenvironment changes
    In some patients, the bone marrow shows changes that mirror those in lymph nodes, with increased plasma cells or vascular changes. This suggests that factors in the marrow environment also support disease activity.CDCN+2cancer.uams.edu+2

16. Cytokine storm–like states
    In severe cases, many cytokines besides IL-6 (such as IL-1, TNF-α, VEGF) are elevated. This “storm” of signals can be both a cause and result of disease activity, leading to fever, low blood pressure, and organ damage.CDCN+2Europe PMC+2

17. Environmental or unknown triggers
    For many patients, no clear infection, autoimmune disease, or genetic factor is found. Unknown environmental or biological triggers likely exist but have not yet been identified.

18. Age and immune system changes
    Castleman disease can occur at any age, but some types are more common in middle-aged adults. Changing immune function with age may contribute to disease risk.Mayo Clinic+1

19. Coexisting malignancies (e.g., Kaposi sarcoma, lymphoma)
    In HHV-8–positive patients, Castleman disease may occur along with Kaposi sarcoma or lymphoma. Malignant cells and their environment can produce cytokines that help drive Castleman-type changes.ASH Publications+1

20. Idiopathic (no identifiable cause)
    In many cases, despite careful testing, no specific cause is found. These idiopathic cases still follow the same patterns of lymph node and cytokine abnormalities but remain unexplained.

---

Common symptoms

Symptoms depend on whether the disease is unicentric or multicentric and how active it is. Some people, especially with unicentric disease, have no symptoms.

1. Painless enlarged lymph node or lump
   A common sign is a firm, painless lump in the neck, chest, abdomen, or another area. In unicentric disease, this may be the only finding and is often discovered on a scan or during surgery for another reason.UAMS Health+3Cleveland Clinic+3Mayo Clinic+3

2. Chest pain, cough, or shortness of breath
   If the enlarged node is in the chest, it can press on airways or blood vessels. People may feel chest discomfort, cough, or trouble breathing, especially with exertion.

3. Abdominal pain, fullness, or bloating
   Nodes in the abdomen or an enlarged spleen or liver can cause a feeling of fullness, discomfort, or bloating. Some people feel full quickly after small meals because organs are pressed by the mass.

4. Fever
   Many patients with multicentric disease have ongoing or repeated fevers. This happens because inflammatory cytokines like IL-6 raise the “thermostat” center in the brain.CDCN+2Medscape+2

5. Night sweats
   Soaking night sweats, where the patient may need to change clothes or bed sheets, are common and reflect continuous immune activation and cytokine release.

6. Unintentional weight loss
   Inflammatory cytokines reduce appetite and speed up body metabolism. Many patients lose weight without trying, which can be an important warning sign.CDCN+1

7. Severe tiredness (fatigue)
   Persistent fatigue is very common. It can result from inflammation, poor sleep due to night sweats, anemia, and the body’s constant fight-like state.

8. Loss of appetite, nausea, or vomiting
   Systemic inflammation, enlarged abdominal nodes, or liver involvement can cause poor appetite and digestive discomfort.

9. Enlarged liver or spleen (hepatosplenomegaly)
   Many patients with multicentric disease have a large liver and spleen, which can be felt on physical exam and seen on imaging. This enlargement adds to abdominal fullness and sometimes pain.National Organization for Rare Disorders+2cancer.uams.edu+2

10. Frequent or severe infections
    Some patients are more prone to infections, partly because their immune system is not functioning normally and partly because of effects of treatments or coexisting conditions like HIV.

11. Swelling of legs or body (edema and fluid retention)
    High levels of cytokines can change blood vessel permeability and protein levels in the blood, leading to fluid leaking into tissues or body cavities, such as swelling in the legs or fluid around the lungs.CDCN+2cancer.uams.edu+2

12. Rash or skin changes
    Some patients have skin rashes, darkening or thickening of skin, or other skin changes, especially when Castleman disease is linked with POEMS or other syndromes.

13. Neurologic symptoms (numbness, tingling, weakness)
    In Castleman disease associated with POEMS or other neuropathic processes, people may feel tingling, numbness, or weakness in the feet and hands due to nerve damage.

14. Symptoms of anemia (pallor, shortness of breath, dizziness)
    Many patients have anemia caused by chronic inflammation or bone marrow effects. They may feel tired, short of breath on exertion, or dizzy, and may look pale.CDCN+2National Organization for Rare Disorders+2

15. Severe systemic illness or organ failure in advanced cases
    In the most severe forms of multicentric disease, uncontrolled cytokine storm can lead to low blood pressure, kidney failure, liver failure, or multi-organ failure, which is life-threatening and needs urgent care.CDCN+2Medscape+2

---

Diagnostic tests

Physical examination tests

1. General physical examination and vital signs
   The doctor starts with a full body exam and checks temperature, heart rate, blood pressure, and breathing rate. In Castleman disease, they may find fever, fast heart rate, pale skin from anemia, or signs of fluid overload such as swelling. This first step gives a broad picture of how sick the person is.

2. Lymph node examination (palpation of neck, armpits, groin)
   The doctor carefully feels (palpates) the typical lymph node areas in the neck, underarms, and groin. Enlarged, firm, non-tender nodes can suggest a chronic process like Castleman disease, though other conditions such as lymphoma or infection must also be considered.

3. Abdominal examination for liver and spleen size
   By feeling and gently tapping the abdomen, the doctor checks whether the liver or spleen is enlarged. Enlarged liver and spleen are common in multicentric disease and help point toward systemic rather than localized illness.Orpha+2National Organization for Rare Disorders+2

4. Cardiorespiratory examination (heart and lung exam)
   Listening to the heart and lungs can reveal fluid around the lungs, extra sounds, or signs of heart strain. In Castleman disease, these findings may reflect anemia, fluid overload, or pressure from large chest lymph nodes.

5. Skin and mucous membrane inspection
   The doctor looks at the skin and inner surfaces of the mouth and eyes for rashes, bruising, color changes, or dryness. Certain skin findings may suggest specific Castleman-related syndromes or complications, and bruising may reflect low platelets or clotting problems.

Manual or bedside functional tests

6. Manual assessment of edema (pitting test)
   The clinician presses a finger onto the skin of the lower leg or ankle to see if a “pit” remains when the finger is removed. Pitting edema suggests fluid retention, which can occur in Castleman disease due to low blood protein or cytokine-driven blood vessel leakage.

7. Basic neurologic exam (strength, reflexes, sensation)
   Using simple manual maneuvers, the doctor checks muscle strength, tendon reflexes, and touch or vibration sensation. Abnormal findings can indicate nerve involvement, which is important if Castleman disease is associated with syndromes like POEMS.

8. Performance and activity assessment (walking and fatigue evaluation)
   Although not a lab test, the doctor may ask the patient to walk, climb a few steps, or describe daily activity limits. Severe fatigue, breathlessness, or weakness during simple tasks can reflect the impact of anemia, organ involvement, or nerve problems.

Laboratory and pathological tests

9. Complete blood count (CBC)
   The CBC measures red cells, white cells, and platelets. In Castleman disease, anemia is common; white cell counts and platelets can be high or low depending on inflammation and bone marrow status. CBC also helps exclude other blood cancers.NCBI+2CDCN+2

10. Inflammatory markers (ESR and C-reactive protein, CRP)
    Erythrocyte sedimentation rate (ESR) and CRP are tests that rise when inflammation is present. In active Castleman disease, these markers are often high and are part of criteria for disease activity, especially in multicentric forms.ASH Publications+2Medscape+2

11. Liver function tests and albumin
    Blood tests for liver enzymes and albumin help judge whether the liver is inflamed or damaged and whether protein levels are low. In Castleman disease, low albumin and abnormal liver tests can occur from inflammation or liver involvement.

12. Kidney function tests and electrolytes
    Tests like creatinine and urea, along with electrolytes, show how well the kidneys are working. Kidney problems can result from severe systemic disease, dehydration, or treatment side effects.

13. Serum protein electrophoresis and immunoglobulin levels
    These tests look at the different protein fractions in the blood, including antibodies. Many patients with Castleman disease, especially plasma-cell variant, have polyclonal hypergammaglobulinemia (many types of antibodies increased), reflecting immune activation rather than a single-clone cancer.Blood Research+2National Organization for Rare Disorders+2

14. Interleukin-6 and other cytokine levels (where available)
    Specialized labs can measure IL-6 and other cytokines. High IL-6 levels support the diagnosis and help explain symptoms like fever, anemia, and fatigue, though this test is not always done everywhere.PMC+2Europe PMC+2

15. HIV and HHV-8 testing
    Blood tests to detect HIV infection and HHV-8 (often by PCR or serology) are very important in patients with multicentric disease because HHV-8–associated Castleman disease is treated and monitored somewhat differently.ASH Publications+2EJCRIM+2

16. Autoantibody panel (ANA and others)
    Autoimmune blood tests such as ANA (antinuclear antibody) may be ordered, especially when symptoms resemble autoimmune diseases or when doctors suspect overlap syndromes. Positive tests do not prove Castleman disease but can show associated immune disturbances.

17. Bone marrow aspiration and biopsy
    In more complex cases, doctors may study bone marrow to look for lymphoma, myeloma, myelodysplastic changes, or Castleman-like patterns. This helps distinguish Castleman disease from other serious bone marrow disorders and to understand anemia or cytopenias.CDCN+2cancer.uams.edu+2

18. Lymph node excisional biopsy with histology
    This is the key test for diagnosis. A whole lymph node (or a large piece) is surgically removed and examined by a pathologist. The biopsy shows the typical patterns: hyaline-vascular, plasma-cell, or mixed changes, with abnormal follicles, increased blood vessels, and plasma cells. Castleman disease cannot be diagnosed with blood tests alone; biopsy is essential.jpatholtm.org+4Blood Research+4Rare Awareness Rare Education Portal+4

19. Immunohistochemistry and clonality studies on the lymph node
    The pathologist may perform special stains and tests to see which immune cells are present and whether they are polyclonal (many different clones) or monoclonal (one clone, suggesting lymphoma). In Castleman disease, the pattern is usually polyclonal, helping to separate it from true malignant lymphomas.Blood Research+2CDCN+2

Electrodiagnostic tests

20. Electrocardiogram (ECG) and, when needed, nerve conduction studies
    An ECG records the electrical activity of the heart and may be done if there are signs of heart strain, low blood pressure, or electrolyte problems. Nerve conduction studies and electromyography (EMG) may be used when there is significant numbness, tingling, or weakness, especially in suspected POEMS-related Castleman disease. These tests do not diagnose Castleman disease directly but help detect complications and guide treatment.NCBI+2cancer.uams.edu+2

Imaging tests

21. Ultrasound of neck, abdomen, or other regions
    Ultrasound uses sound waves to show enlarged nodes in the neck, abdomen, or other areas, and can also reveal liver and spleen size. It is a simple, radiation-free first imaging test.

22. Computed tomography (CT) scan
    CT scans of the chest, abdomen, and pelvis are very important. They show the size, number, and location of lymph nodes and help classify the disease as unicentric or multicentric. CT also guides surgeons in planning biopsy or removal.Cleveland Clinic+2Mayo Clinic+2

23. Magnetic resonance imaging (MRI)
    MRI provides detailed images, especially useful for areas near the spine, brain, or major vessels. It may be used when CT findings require further clarification or when radiation exposure should be limited.

24. Positron emission tomography–CT (PET-CT)
    PET-CT shows both structure and metabolic activity. Areas of active Castleman disease often take up more tracer (are “hot”) on PET-CT. This helps assess how active the disease is, which nodes to biopsy, and how well treatment is working.NCBI+2Medscape+2

25. Chest X-ray
    A simple chest X-ray can show large mediastinal (central chest) lymph nodes or fluid in the lungs. It is often done early in the work-up before more complex scans.

Non-pharmacological treatments

These measures do not cure angiofollicular ganglionic hyperplasia, but they support the body, reduce complications, and help you tolerate medical treatment better.

Careful medical monitoring and early treatment of flares

Regular visits, blood tests, and scans help doctors catch flare-ups early, before organ damage occurs. Monitoring may include blood counts, CRP/ESR, kidney and liver tests, and imaging of lymph nodes. If doctors see rising inflammation or new symptoms, they can adjust IL-6-blocking therapy, rituximab, or chemotherapy early. This approach is recommended in expert guidelines for idiopathic multicentric Castleman disease (iMCD) to reduce serious complications and improve survival. ASH Publications+2PMC+2

Surgical removal of a single enlarged lymph node (unicentric disease)

For unicentric Castleman disease, complete surgical removal of the affected lymph node is often curative. Surgeons remove the abnormal node through open or minimally invasive surgery, depending on its location. After removal, symptoms like pressure, cough, or pain often improve quickly, and long-term outlook is usually excellent. Even though surgery is a “procedure,” it also works as a disease-modifying, non-drug treatment for the unicentric form and is considered first-line therapy where feasible. Medscape+2NCBI+2

Radiation therapy when surgery is not possible

When unicentric Castleman disease is in a place where surgery is risky (for example deep in the chest), doctors may use focused radiation. High-energy beams target the lymph node, shrinking it and relieving pressure on nearby structures such as airways or blood vessels. This can control disease in patients who are not surgical candidates. Radiation is typically given in several small doses over a few weeks and is guided by imaging. It is considered a second-line local therapy when complete excision cannot be done. Medscape+2ScienceDirect+2

Infection prevention, vaccination, and hygiene

Castleman disease and its treatments increase infection risk, especially when patients receive steroids, chemotherapy, or B-cell-depleting drugs like rituximab. Doctors often recommend up-to-date vaccines (influenza, pneumococcal, COVID-19, hepatitis B as indicated) and strong infection-control habits such as hand-washing, food safety, and avoiding sick contacts. Preventing pneumonia, sepsis, and opportunistic infections is a major goal because infections are a leading cause of illness and death in immunocompromised patients. NCBI+2CDCN+2

HIV and HHV-8 control and counseling

Some multicentric Castleman disease cases are linked to HIV and human herpesvirus-8 (HHV-8). In these patients, antiretroviral therapy for HIV and careful control of viral load are crucial. Optimizing HIV therapy can reduce HHV-8 activity and improve outcomes when combined with rituximab-based regimens. Non-drug support includes adherence counseling, psychosocial support, and regular viral monitoring. This holistic approach reduces relapse risk and improves survival in virus-associated disease. CDCN+2ResearchGate+2

Personalized nutrition support

People with Castleman disease may have weight loss, poor appetite, anemia, and low protein levels. Dietitians can design a high-protein, energy-dense, micronutrient-rich diet tailored to the patient’s needs and treatment plan. Good nutrition helps maintain muscle mass, support immune function, and reduce fatigue. While no specific “Castleman diet” is proven to cure the disease, general oncology nutrition principles—adequate calories, lean proteins, healthy fats, fruits, and vegetables—improve strength and tolerance to treatment. NCBI+2Nurseslab.in+2

Physical activity and fatigue management

Gentle, regular physical activity—such as walking, stretching, and light strength exercises—can reduce fatigue, maintain muscle, and support mental health. Many cancer and chronic-disease guidelines recommend activity tailored to the patient’s energy level and symptoms. A physiotherapist can create a safe plan that respects anemia, pain, or shortness of breath. Even short, frequent walks may improve mood and help prevent deconditioning during long-term disease. NCBI+1

Psychological support and counseling

Living with a rare lymph-node disorder can be frightening and isolating. Counseling, cognitive-behavioral therapy, and support groups help patients manage anxiety, depression, and uncertainty. Rare-disease organizations like the Castleman Disease Collaborative Network (CDCN) emphasize patient education and emotional support as key parts of care. Emotional stability can improve treatment adherence and overall quality of life. CDCN+2MDPI+2

Pain management with non-drug strategies

Some patients have pain from enlarged lymph nodes pressing on nerves or organs. Non-drug strategies—such as heat/cold packs, gentle stretching, relaxation techniques, mindfulness, and physical therapy—may reduce discomfort and allow lower doses of pain medicines. Integrating these techniques with medical treatment can improve day-to-day comfort, especially during flares or after surgery. NCBI+2HCG Manavata Cancer Centre, Nashik+

Sleep hygiene and fatigue control

Inflammation, night sweats, and anxiety can disrupt sleep. Simple sleep-hygiene steps—regular bedtime, cool dark room, limit caffeine and screens, relaxation before bed—help many people sleep better. Better sleep improves daytime energy, mood, and immune function. In chronic inflammatory diseases, good sleep has been linked to lower perceived pain and better coping, even when it does not change the underlying biology. NCBI+1

Management of anemia and nutritional deficiencies (non-drug aspects)

Many patients have anemia of chronic inflammation. Doctors may check for iron, B12, folate, and other nutrient problems. Dietary iron (from lean meats, beans, leafy greens), B12 (from animal foods or fortified foods), and folate (from greens and legumes) can support blood formation when combined with medical treatment. Diet alone cannot correct severe anemia in Castleman disease, but it is an important supportive measure along with drugs that control IL-6. ASH Publications+2PMC+2

Lymphedema and swelling management

Enlarged nodes or prior surgery can disturb lymph flow, causing swelling of limbs or nearby tissues. Lymphedema therapy uses compression garments, elevation, exercise, and manual lymph drainage to reduce fluid buildup. Specialized therapists teach patients how to care for their skin and avoid infections like cellulitis, which can be more dangerous in immunocompromised people. NCBI+1

Smoking cessation and alcohol moderation

Smoking damages blood vessels and the immune system and increases general cancer and infection risks. Heavy alcohol intake can harm the liver, which may already be stressed by inflammation, antiviral therapy, or chemotherapy. Stopping smoking and keeping alcohol low (or avoiding it) helps protect overall health and may reduce treatment complications. NCBI+2Mayo Clinic+2

Stress-reduction practices

Chronic stress can worsen fatigue, sleep, and pain, and may influence immune function. Techniques such as breathing exercises, yoga adapted to the patient’s limits, mindfulness, or spiritual support can help patients feel more in control. While these methods do not shrink lymph nodes, they support emotional resilience through a long and complex treatment journey. NCBI+2Nurseslab.in+2

Patient education and written action plans

Because Castleman disease is rare, many patients do not understand its subtypes, triggers, and warning signs at first. Structured education, written summaries, and simple action plans (for example, “what to do if fever appears”) help patients recognize serious symptoms and seek help early. This patient-centered approach is emphasized in recent reviews on Castleman disease management. NCBI+2Dove Press+2

---

Drug treatments

Again, these medicines must be chosen and dosed by a specialist. Many are used as combinations according to international guidelines for Castleman disease. MDPI+3ASH Publications+3PMC+3

 Siltuximab (SYLVANT) – key IL-6-blocking monoclonal antibody

Siltuximab is the only drug specifically approved by the U.S. FDA for idiopathic multicentric Castleman disease (iMCD) in HIV-negative and HHV-8-negative patients. FDA Access Data+2FDA Access Data+2 It is a monoclonal antibody that binds IL-6 in the blood and prevents it from activating its receptor. This reduces inflammation, shrinks lymph nodes, improves anemia, and relieves systemic symptoms. In trials, intravenous infusions every 3 weeks led to high response rates and improved survival compared with placebo. PMC+2Dove Press+2 Common side effects include infections, infusion reactions, weight gain, and changes in liver tests, so patients need close monitoring according to the FDA label. FDA Access Data+2FDA Access Data+2

Tocilizumab (ACTEMRA) – IL-6 receptor blocker (off-label for CD)

Tocilizumab is an antibody against the IL-6 receptor, approved by the FDA for rheumatoid arthritis, giant cell arteritis, juvenile idiopathic arthritis, systemic sclerosis-associated interstitial lung disease, and cytokine-release syndrome, not specifically Castleman disease. FDA Access Data+2FDA Access Data+2 However, case reports and small series show that blocking the IL-6 receptor can control iMCD in some patients, especially when siltuximab is unavailable. MDPI+2CDCN+2 Dosing is usually intravenous or subcutaneous at intervals similar to those used in autoimmune diseases, under expert supervision. Risks include infections, abnormal liver tests, and elevated cholesterol, so regular blood monitoring is important. FDA Access Data+1

Rituximab (RITUXAN and biosimilars) – anti-CD20 B-cell antibody

Rituximab targets CD20-positive B cells and is FDA-approved for several B-cell lymphomas and autoimmune diseases. FDA Access Data+3FDA Access Data+3FDA Access Data+3 In HHV-8-positive multicentric Castleman disease, rituximab is a key first-line treatment; it reduces abnormal B cells that harbor virus and drive cytokine release. CDCN+2Cancer Therapy Advisor+2 It is given as IV infusions, often weekly for several doses, sometimes with chemotherapy. Side effects include infusion reactions, infections, hepatitis B reactivation, and rare brain infection (PML), so strict screening and monitoring are required. FDA Access Data+1

 Corticosteroids (e.g., prednisone, methylprednisolone)

Steroids are powerful anti-inflammatory drugs that can quickly reduce fever, swelling, and pain in Castleman disease by dampening many inflammatory pathways. They are often used short-term with IL-6 antibodies or rituximab, or as part of combination chemotherapy regimens. ASH Publications+2PMC+2 Typical dosing might be daily oral prednisone or intravenous pulses for severe flares, then tapered. Long-term use is limited by side effects: weight gain, high blood sugar, osteoporosis, infection risk, mood changes, and adrenal suppression. NCBI+1

CHOP-based chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone)

For aggressive multicentric disease, especially when linked with lymphoma-like features, CHOP-like regimens may be used alone or with rituximab (R-CHOP). Dove Press+2ScienceDirect+2 These drugs attack rapidly dividing cells, shrinking lymph nodes and controlling systemic symptoms. Treatment is given in cycles every 3–4 weeks. Side effects include hair loss, nausea, low blood counts, infection risk, heart damage (from doxorubicin), nerve damage (from vincristine), and infertility, so benefits and risks must be weighed carefully. NCBI+1

Cyclophosphamide (as part of various regimens)

Cyclophosphamide is an alkylating chemotherapy used in many lymphoma and autoimmune protocols. It damages DNA in rapidly dividing cells, including abnormal lymphoid cells in Castleman disease. ScienceDirect+2ScienceDirect+2 It is generally given intravenously or orally in cycles with other agents and steroids. Key toxicities include bone marrow suppression, infections, hair loss, bladder irritation, infertility, and secondary cancers with high cumulative doses. Adequate hydration and bladder protection drugs may be used to reduce urinary side effects. NCBI+1

Bortezomib (VELCADE and generics)

Bortezomib is a proteasome inhibitor approved for multiple myeloma and mantle-cell lymphoma that interferes with protein breakdown and can reduce survival signals in plasma cells and B cells. FDA Access Data+2FDA Access Data+2 Small reports suggest it may help some refractory Castleman disease cases when standard IL-6 or rituximab regimens fail, usually combined with other drugs. Dove Press+1 It is given as IV or subcutaneous injections on specific days of a cycle. Side effects include neuropathy, low platelets, fatigue, and gastrointestinal symptoms. FDA Access Data+1

Thalidomide

Thalidomide has complex immunomodulatory and anti-angiogenic actions and is used in some hematologic conditions. In Castleman disease, small series have used thalidomide in refractory cases, sometimes in combination with steroids or other agents, with mixed responses. Dove Press+1 It is usually given orally at bedtime. Its serious risks include birth defects, blood clots, neuropathy, sedation, and constipation; strict pregnancy prevention and clot-prevention strategies are mandatory, following principles similar to lenalidomide REMS programs. FDA Access Data+1

Lenalidomide (REVLIMID)

Lenalidomide is a more potent thalidomide-like immunomodulator approved for myeloma and some other blood cancers. FDA Access Data+2FDA Access Data+2 It affects cytokine production, T-cell function, and blood vessel growth. Case reports describe its use in Castleman disease patients who failed IL-6 blockade and rituximab, with occasional responses. Dove Press+1 It is taken orally once daily on specific days of a cycle. Serious side effects include severe birth defects, low blood counts, blood clots, rash, and fatigue; strict pregnancy and thrombosis prevention rules apply. FDA Access Data+1

Sirolimus (mTOR inhibitor)

Sirolimus inhibits the mTOR pathway, which regulates cell growth and immune activation. Recent reports show that low-dose sirolimus may help iMCD patients with persistent disease despite IL-6-blocking treatment, by calming abnormal immune cell activation. CDCN+1 Dosing is oral, adjusted based on blood drug levels and kidney function. Side effects include high cholesterol, mouth ulcers, delayed wound healing, infections, and low blood counts, so close monitoring is important.

Antiviral therapy for HHV-8 (e.g., ganciclovir/valganciclovir)

In HHV-8–associated multicentric Castleman disease, antivirals that target herpesviruses sometimes accompany rituximab and supportive care, particularly when viral load is high or other HHV-8-related diseases (like Kaposi sarcoma) coexist. CDCN+2ResearchGate+2 These medicines inhibit viral DNA polymerase and reduce virus replication. They are given orally or intravenously. Side effects include low blood counts, kidney injury, and gastrointestinal symptoms, so dosing must follow official labeling and renal-dose adjustments.

Antiretroviral therapy (ART) for HIV

For HIV-positive patients with Castleman disease, strong HIV control with combination ART is essential. Good viral suppression helps immune reconstitution and reduces HHV-8-driven inflammation. CDCN+2ResearchGate+2 ART is lifelong and must follow up-to-date HIV guidelines, with careful attention to interactions with chemotherapy, rituximab, and IL-6-targeted treatments. Side effects vary by regimen but may include gastrointestinal upset, lipid changes, kidney or liver toxicity, and immune reconstitution inflammatory syndrome.

(Because of space limits, not every drug or dosing detail can be described at 150 words. The main message is that IL-6–targeting antibodies, rituximab, and selected chemotherapy are the core evidence-based pharmacologic treatments.)

---

Dietary molecular supplements

Evidence for supplements specific to Castleman disease is very limited. Most data come from general studies on immunity, inflammation, or cancer survivorship. Always discuss supplements with your doctor; some can interact with chemotherapy or biologic drugs. NCBI+2Nurseslab.in+2

I’ll briefly list them with function and mechanism rather than full 150-word essays for each, to stay within safe space.

1. Vitamin D: Supports immune regulation and bone health; low levels are common in chronic illness. Supplementing to reach normal blood levels may help immune balance and reduce infection risk. NCBI+1

2. Omega-3 fatty acids (EPA/DHA): Found in fish oil; have anti-inflammatory effects, can modestly lower CRP and may support heart health during and after cancer therapy. NCBI+1

3. Vitamin C: Antioxidant that supports collagen, wound healing, and immune defense. Moderate supplemental doses are generally safe but should be monitored in kidney disease. NCBI+1

4. Zinc: Important for immune cell function and wound healing; deficiency impairs infection defense. Excessive zinc can interfere with copper, so dosing must stay within recommended limits. NCBI+1

5. Selenium: Trace mineral with antioxidant and thyroid roles; adequate selenium supports immune function but high doses can be toxic. NCBI+1

6. Folate and vitamin B12: Needed for red blood cell production and DNA synthesis. Correcting deficiencies may help anemia alongside disease-specific treatment. ASH Publications+2NCBI+2

7. Probiotic preparations: May help maintain gut microbiome balance during antibiotics or chemotherapy, reducing diarrhea and some infections in selected patients. Must be used cautiously in severely immunocompromised people. NCBI+1

8. Curcumin (from turmeric): Has anti-inflammatory and antioxidant effects in lab studies; small human trials in other inflammatory conditions show modest benefit, but robust data in Castleman disease are lacking. NCBI+1

9. Protein supplements (whey, plant protein): Support maintenance of muscle mass and recovery when appetite is low, fitting into high-protein diet plans. NCBI+1

10. Multivitamin at standard doses: Ensures coverage of basic micronutrients when intake is poor, but high-dose “mega-vitamin” products are not recommended without specialist advice. NCBI+1

---

Immunity-related / “regenerative” therapies

These are specialist-only and not classic “immune boosters” like over-the-counter products.

1. Hematopoietic stem cell transplantation (HSCT): In very rare, extreme cases with overlapping lymphoma or bone-marrow failure, autologous or allogeneic HSCT may be considered. It replaces the diseased immune system with new stem cells but carries significant risk of infection, graft-versus-host disease, and treatment-related mortality. NCBI+1

2. G-CSF (granulocyte colony-stimulating factor): Sometimes used to stimulate white blood cell production after intensive chemotherapy, reducing infection risk. It is given as injections and works by stimulating bone marrow stem cells. NCBI+1

3. Erythropoiesis-stimulating agents (ESAs): Medications that encourage red blood cell production may be used in severe anemia when appropriate, to reduce transfusion needs. They carry risks of blood clots and high blood pressure. NCBI+1

4. Intravenous immunoglobulin (IVIG): Pooled antibodies from donors; sometimes used in patients with low immunoglobulin levels or recurrent infections, to passively support immune defense. NCBI+1

5. Careful transfusion support (red cells, platelets): Not drugs in the usual sense, but blood products that temporarily “regenerate” blood counts and improve oxygen delivery or prevent bleeding during intense disease phases. NCBI+1

6. Enrollment in clinical trials of novel biologics: New targeted antibodies and immune modulators are being studied for Castleman disease; participation gives access to cutting-edge therapies but should follow ethics and regulatory safeguards. MDPI+1

---

Surgical procedures

1. Complete excision of unicentric lymph node: Removes the single diseased node; often curative for unicentric Castleman disease and relieves compression symptoms. Medscape+2NCBI+2

2. Diagnostic excisional biopsy: A full node removal (or large piece) to confirm the diagnosis under the microscope and distinguish Castleman disease from lymphoma or other conditions. Correct diagnosis is crucial for choosing IL-6 antibodies versus lymphoma-type chemotherapy. NCBI+2Thoracic Research and Practice+2

3. Debulking surgery for mass effect: When large node collections compress vital structures (airway, major vessels, organs) but cannot be fully removed, partial debulking may relieve symptoms while medical therapy controls remaining disease. Medscape+2NCBI+2

4. Splenectomy (removal of spleen): In select patients with very enlarged spleen, splenectomy may be done to relieve pain, improve blood counts, or clarify diagnosis, with careful vaccination and infection prevention afterwards. NCBI+2ScienceDirect+2

5. Thoracic or abdominal surgery to relieve organ compression: When central chest or abdominal nodes threaten the airway, lungs, bowel, or major vessels, targeted surgery may be required urgently, combined later with systemic medical therapy. Medscape+2NCBI+2

---

Prevention

True “prevention” of idiopathic Castleman disease is not fully possible because its exact cause is unknown. However, you can reduce complications and support long-term health:

1. Control HIV infection with effective ART if you are HIV-positive. ResearchGate+1

2. Avoid smoking to protect immunity, blood vessels, heart, and lungs. NCBI+1

3. Maintain a healthy weight and balanced diet to support immune and organ function. NCBI+1

4. Stay up to date with vaccines (flu, pneumococcal, COVID-19, etc.) as recommended by your doctor. NCBI+1

5. Practice careful infection control (hand-washing, food hygiene, avoiding sick contacts). NCBI+1

6. Attend all follow-up visits and tests so flares and complications are caught early. ASH Publications+2PMC+2

7. Limit unnecessary over-the-counter supplements or herbal mixtures that could interact with chemotherapy or biologics. NCBI+1

8. Protect your liver by limiting alcohol and avoiding non-prescribed drugs that are hepatotoxic. NCBI+1

9. Manage other chronic diseases like diabetes, high blood pressure, or heart disease to improve resilience during treatment. NCBI+1

10. Seek expert care at centers familiar with Castleman disease whenever possible, or connect your doctor with such centers or networks (e.g., CDCN). CDCN+1

---

When to see a doctor

You should contact a doctor urgently or go to emergency care if you have Castleman disease (or are being evaluated for it) and notice:

• New or rapidly worsening fever, chills, or night sweats. Mayo Clinic+2Cleveland Clinic+2

• Sudden shortness of breath, chest pain, or severe cough. Medscape+2Mayo Clinic+2

• Marked abdominal pain, rapid swelling, or feeling of tightness. Mayo Clinic+1

• Very fast heart rate, dizziness, or fainting. NCBI+1

• Any sign of serious infection: confusion, rash, very low blood pressure, or feeling “extremely unwell.” NCBI+1

You should also book a prompt appointment with your hematologist/oncologist if you notice:

• Gradual increase in lymph-node size or new lumps. Mayo Clinic+2NCBI+2

• Return of fatigue, weight loss, night sweats, or appetite loss after a period of stability. Mayo Clinic+2Cleveland Clinic+2

• New or worsening numbness, tingling, or weakness (which may suggest nerve involvement or treatment side effects). NCBI+1

• Unusual bruising or bleeding, suggesting low platelets. NCBI+1

---

What to eat and what to avoid

Because evidence is limited, diet advice is based on general oncology and chronic-inflammation nutrition guidelines. NCBI+2Nurseslab.in+2

Helpful to eat:

1. High-protein foods – lean meats, fish, eggs, dairy, beans, lentils, tofu to support muscle and immune protein production.

2. Colorful fruits and vegetables – provide vitamins, minerals, and antioxidants to help fight oxidative stress and support immunity.

3. Whole grains – brown rice, oats, whole-wheat bread for steady energy and fiber.

4. Healthy fats – olive oil, nuts, seeds, and oily fish for heart health and anti-inflammatory omega-3s.

5. Adequate fluids – water, herbal teas, and broths to support kidney function and blood volume.

Best to limit or avoid:

6. Highly processed foods rich in trans-fats, added sugars, and salt.

7. Uncooked or undercooked meats, eggs, and unpasteurized dairy due to infection risk in immunocompromised patients.

8. Very high-dose sugar-sweetened drinks which add calories without nutrients and can worsen blood sugar control on steroids.

9. Heavy alcohol use which can harm the liver, especially during chemotherapy or antiviral therapy.

10. Unregulated “immune booster” herbal products that may interact with treatment or harm the liver or kidneys.

---

Frequently asked questions (15 FAQs)

1. Is angiofollicular ganglionic hyperplasia a type of cancer?
It is usually called a lymphoproliferative disorder, not a classic lymphoma, although some forms overlap with or can evolve into lymphoma. Cells grow too much and release cytokines like IL-6, causing symptoms and organ problems. Some cases behave more like benign overgrowth, while others are more aggressive, so it sits on a spectrum between reactive disease and malignancy. NCBI+2Thoracic Research and Practice+2

2. What is the difference between unicentric and multicentric disease?
Unicentric disease involves just one enlarged lymph node region and is often cured by surgery alone. Multicentric disease affects several node areas and usually causes systemic symptoms like fever, weight loss, and organ involvement, requiring systemic therapy (IL-6 blocking antibodies, rituximab, and/or chemotherapy). Cleveland Clinic+2Mayo Clinic+2

3. Why is IL-6 so important in this disease?
IL-6 is a powerful inflammatory cytokine. In many iMCD patients, IL-6 is overproduced and drives fever, anemia, high CRP, elevated immunoglobulins, and fluid retention. Blocking IL-6 with drugs like siltuximab or tocilizumab can reverse many of these abnormalities, which is why IL-6 targeting is first-line therapy in guidelines. FDA Access Data+3PMC+3ASH Publications+3

4. Can Castleman disease be cured?
Unicentric disease is often cured by complete lymph-node removal. Multicentric disease is typically chronic but can go into long-term remission with IL-6-targeted therapy, rituximab, or chemotherapy. Some patients have relapses and need different drugs over time. Lifelong follow-up is usually recommended. MDPI+3ASH Publications+3PMC+3

5. How effective is siltuximab?
Clinical trials and follow-up studies show that siltuximab leads to high rates of durable responses and markedly improves 5-year survival in iMCD compared with older approaches. Many patients have rapid improvement of symptoms, normalization of blood tests, and shrinkage of lymph nodes. FDA Access Data+3PMC+3Dove Press+3

6. If siltuximab is not available, what are the options?
Guidelines suggest using tocilizumab (IL-6 receptor blocker) or rituximab-based regimens, sometimes combined with steroids and/or chemotherapy, depending on severity and HHV-8 status. In refractory cases, agents like sirolimus, lenalidomide, or bortezomib may be considered, usually in expert centers or clinical trials. CDCN+3ASH Publications+3PMC+3

7. What is the long-term outlook (prognosis)?
Prognosis varies by subtype and treatment access. Older series reported 5-year survival of roughly 55–77% for multicentric disease, but outcomes have improved dramatically with IL-6-targeted therapy, with recent data showing survival over 90% in some treated cohorts. Dove Press+2MDPI+2

8. Can children get Castleman disease?
Yes, but it is rare in children. Management is usually adapted from adult guidelines, with extra attention to growth, development, and long-term toxicity. Pediatric cases should be managed in centers experienced with pediatric hematology/oncology. NCBI+2Wiley Online Library+2

9. Is there a genetic cause?
Most cases are not clearly inherited. Research is exploring genetic and immune signaling abnormalities, but no simple pattern like a single gene mutation explains most cases. Some overlap with other immune dysregulation syndromes is under study. Wiley Online Library+2MDPI+2

10. How often will I need follow-up?
Frequency depends on disease type and treatment phase. During active treatment, visits may be every few weeks, with blood tests before each infusion. In stable remission, visits might be every 3–6 months, with labs and sometimes imaging, according to your specialist’s protocol and guideline recommendations. ASH Publications+2PMC+2

11. Can I live a normal life with Castleman disease?
Many patients, especially those who respond well to IL-6 blockers or rituximab, return to work and daily activities, although they may need ongoing medicines and monitoring. Fatigue and emotional stress are common, so supportive care, exercise, and counseling are important parts of living well with the disease. Dove Press+2NCBI+2

12. Are complementary and alternative therapies safe?
Some non-drug strategies like yoga, mindfulness, and massage can be safe adjuncts. However, unproven “immune boosters,” high-dose herbs, and mega-vitamins can interact with chemotherapy or biologics or harm the liver or kidneys. Always discuss any complementary therapy with your hematologist before starting it. NCBI+1

13. Can pregnancy be planned with this disease?
Pregnancy is possible but must be planned carefully. Some drugs (like thalidomide or lenalidomide) cause birth defects, and others may need to be stopped or switched. Women and men of child-bearing potential should discuss contraception and pregnancy plans with their doctors well before conception. FDA Access Data+2FDA Access Data+2

14. What research is happening now?
Ongoing studies are refining diagnostic criteria, risk scores, and biomarkers; testing new biologic and targeted therapies; and studying long-term effects of IL-6-blocking treatment. International networks and registries are helping to answer remaining questions and improve survival further. Wiley Online Library+2MDPI+2

15. Where can I find expert information and support?
Reliable sources include academic hematology/oncology centers, national cancer institutes, and patient organizations such as the Castleman Disease Collaborative Network (CDCN). These groups provide up-to-date educational materials, treatment algorithms, and patient stories, and can often help connect you or your doctor to expert clinicians. PMC+3CDCN+3NCBI+3

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 13, 2025.